8-KAnnualMeetingMay2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K    
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 6, 2015
    
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)

Delaware
000-27756
13-3648318
------------------
------------------
---------------
(State or other jurisdiction of
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)


352 Knotter Drive, Cheshire, Connecticut 06410
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code:    (203) 272-2596
   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))

Item 5.07    Submission of Matters to a Vote of Security Holders.

Alexion Pharmaceuticals, Inc. held its Annual Meeting of Shareholders on May 6, 2015 in New Haven, Connecticut. The results of the matters voted on by the shareholders are set forth below.

1.    The election of directors:
 

Votes For
 
Votes Against or Withheld
 

Abstentions
 
Broker
Non-Votes
 
 
 
 
 
 
 
 
Leonard Bell
176,540,206
 
99,313
 
1,215,400
 
4,946,574
David Brennan
177,382,387
 
36,873
 
435,659
 
4,946,574
M. Michele Burns
177,135,846
 
80,224
 
638,849
 
4,946,574
Christopher Coughlin
177,105,536
 
299,877
 
449,506
 
4,946,574
David Hallal
177,184,493
 
37,263
 
633,163
 
4,946,574
John T. Mollen
176,933,925
 
182,869
 
738,125
 
4,946,574
R. Douglas Norby
175,788,089
 
732,876
 
1,333,954
 
4,946,574
Alvin S. Parven
175,745,811
 
768,777
 
1,340,331
 
4,946,574
Andreas Rummelt
177,278,442
 
43,077
 
533,400
 
4,946,574
Ann M. Veneman
176,552,943
 
619,009
 
682,967
 
4,946,574

2.
The non-binding advisory vote to approve the compensation paid to Alexion’s named executive officers as described in Alexion’s 2015 proxy statement:

Votes For
 

Votes Against
 

Abstentions
 

Broker Non-Votes
 
 
 
 
 
 
 
175,416,687
 
1,947,905
 
490,327
 
4,946,574

3.
Ratification of the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
181,493,307
 
1,079,168
 
229,018

4.
Approval of 2015 Employee Stock Purchase Plan:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
177,278,876
 
342,761
 
233,282

5.
Shareholder proposal requesting the Board of Directors to amend Alexion's governing documents to allow for proxy access:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
87,188,567
 
89,946,367
 
719,985

6.
Shareholder proposal requesting the Board of Directors to amend Alexion's governing documents to give shareholders owning ten percent of Alexion stock the power to call a special meeting:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
79,446,714
 
98,155,603
 
252,602



Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2015
 
ALEXION PHARMACEUTICALS, INC.
 
 
By:    /s/ Michael V. Greco      
Name: Michael V. Greco
Title: Vice President of Law and Corporate Secretary